Keen Vision Acquisition Corp. Annual Report - How They Did This Year

I’m breaking down Keen Vision’s performance this year to help you decide if this company fits your investment strategy.

1. What does this company do?

Keen Vision is a "blank check" company. It doesn't make products or sell services. Instead, it raised $115 million in an initial public offering (IPO) to find and buy a private company. Once they complete a purchase, that private company takes their place on the stock market.

2. The Big News: A Change in Plans

Keen Vision recently changed its strategy. They canceled their planned merger with Medera Inc. On February 26, 2026, they signed a new agreement to merge with Novoheart Group Limited (NVH).

NVH is a biotech firm that uses "MyoChip" technology to simulate human heart tissue for drug testing. This shifts the company’s focus toward high-tech medical research.

3. Who is running the show?

Leaders Kenneth and Jason Wong have deep experience in private equity and global markets. They look for companies in biotechnology, consumer goods, and agriculture that prioritize sustainability. They believe their network in the Asia-Pacific region will help these companies grow by providing better access to clinical trials and manufacturing.

4. Financial Health

Since this is a shell company, it has no sales or profit. Its health depends on the cash in its "Trust Account," which holds about $118 million.

The NVH deal has three main financial requirements:

• Cash Goal: The combined company must have at least $10 million in cash after paying all costs to close the deal.
• Valuation: The deal values NVH at $100 million, though this may change after a final audit.
• Costs: They capped transaction expenses at $700,000 for Keen Vision and $1.3 million for NVH. This protects the cash in the trust account from excessive legal and advisory fees.

5. Key Risks

• Deal Risk: This is not a done deal. They must sign a formal merger agreement by April 10, 2026. If they miss this deadline, the company may liquidate, returning about $10.00 per share to investors.
• Redemption Risk: You have the right to ask for your money back if you dislike the final deal. If too many investors do this, the company might fall below the $10 million cash requirement, causing the deal to collapse.
• Market Volatility: This is a speculative investment. The stock price will likely swing based on whether investors believe the NVH deal will succeed. Since the company has no current operations, the stock price reflects the value of the trust account and the likelihood of a successful merger.

6. Future Outlook

The team is focused on finalizing the NVH agreement by April. If they succeed, your investment will shift from a "blank check" company to a biotech firm. Watch for the "Definitive Proxy Statement" in SEC filings. It will contain the final merger terms and the date for your shareholder vote.

Pro Tip for Investors: Keep a close eye on the SEC filings for the "Definitive Proxy Statement." That document is your best resource for the final terms of the merger, and it will be the official notice for when you need to cast your vote as a shareholder.